|
8 18, a hundred years at Peking University launched a lecture hall in the academic atmosphere of Peking University WBL Dr. Duan Zhenwen, Chinese PLA General Hospital Dr. Ye Ping, and University Hospital in Oslo, Norway DrKjetilRetterstol around Monascus product research are discussed. Well-known cardiovascular Expert Professor Hu Dayi also experts in the field to start the academic discussions. Singapore Wearnes biomedical (WBM), Norway Pharmalogica and Beijing WBL Peking University on behalf of three companies Table And from the University of California, Los Angeles Campus, Singapore Heart Centre and the China-related academic organizations were present at the "Europeans see red yeast rice" campaign. Learned that University Hospital in Oslo, Norway to a study recently completed by the Beijing Peking University WBL Biotech Co., independent research and development production of red yeast rice products HypoCol (name of the drug Xuezhikang domestic sales), for mild high Cholesterol Hyperlipidemia patients and on the western side effects of statins in patients with very good effect, the lipid-lowering efficacy and the world recognized statins quite. Research shows that China Monascus products in the European population in the lipid research to achieve a "zero" breakthrough, Peking University WBL Hypocol also become the first European market has a temporary Bed Proof Monascus products. Peking University WBL Corporation and Singapore WBM, Norway Pharmalogica three companies jointly funded in 2004 by the end of University Hospital in Oslo, Norway lipid official launch of the Department of Clinical Research for the Europeans. The study is an observational HypoCol to mild and mild hypercholesterolemia High blood sugar Patients blood lipids, inflammatory markers and blood sugar effects of three single-center, randomized, double-blind, placebo-controlled clinical study. Study was concluded early this year. Results Show: HypoCol16 weeks after taking the treatment group reduced total cholesterol (TC), low density lipoprotein cholesterol (LDL-C) and apolipoprotein B (APoB) were 16.6%, 24.2% and 23.2% Compared with the control group there was significant difference (P <0.001), the lipid-lowering efficacy and 20mg lovastatin, and fluvastatin 40mg considerable. The incidence of adverse reactions groups did not differ. The results show that, HypoCol apply to patients with mildly high cholesterol and statins in patients with western medicine has side effects. Not long ago, the results of the study in Rome, Italy held the 14th session of the International Symposium of atherosclerotic disease, the formal public Cloth . This is the first time North dimensional letters, conducted in European populations of red koji lipid research, and to HypoCol became the first clinically proven in Europe Monascus products Traditional Chinese medicine Products, but also to promote the Sino-Norwegian economic and trade cooperation and R & D has taken a significant step. Dyslipidemia is an independent cardiovascular disease risk factors, extremely harmful to human health, recent years, as economic development, higher living standards and unhealthy habits, leading to abnormal blood lipid in the world, especially in developing countries is spreading trend, dyslipidemia in the worldwide pandemic, so lipid-lowering drugs to become the world's best-selling drugs in 2005, lipid-lowering drugs global sales of 324 billion U.S. dollars, the treated area for two consecutive years ranked first 1, in which sales of more than one billion U.S. dollars of products have five. Chinese invented the red yeast, foreigners found statins. Monascus China is the hometown of statins is the world's most widely recognized and the use of lipid lowering drugs, red yeast rice contains a natural as a lipid-lowering effect of statins while. WBL Peking University has developed on this basis a series of Monascus products for the treatment of dyslipidemia. WBL Peking University attaches great importance to the quality of red yeast rice products, through fingerprint monitoring to ensure that each batch of finished product in the stability of active ingredient content, which is common with commercial essential difference between red yeast rice, also Beijing-dimensional aspect of the letter in the modernization of Chinese medicine In the domestic front. Peking University WBL focus on evidence-based medicine methodology, the road to promote the academic formation of its own characteristics, achieved fruitful research results. Xuezhikang initial listing, the company launched a long period in China, large sample, multi-center, randomized, double-blind clinical studies, up to 7 years by an average of 4 years of observation, achieved spectacular results - Xuezhikang lower Coronary Heart Disease The risk of death 1 / 3. The study is the first population in the East, for the first time with a large sample of Chinese medicine for clinical research to fill the domestic use of evidence-based medicine for the secondary prevention of coronary heart disease gaps in medical research. WBL Peking University is actively developing the domestic market, to maintain the leading position of domestic lipid lowering drugs also have been concerned about the overseas market as a model of modern Chinese enterprise, Beijing University of Chinese medicine into the international dimension is believed to have done a lot of road try. North-dimensional letter Monascus products in the market in the United States early in the clinical studies done in recent years have in Singapore, Taiwan, the United States and other countries have done a lot of basic and clinical research, confirmed the transfer in different populations lipid efficacy and Security Sex. With the maturity of the domestic market, red yeast rice, foreign scholars and patient awareness of Monascus products and increasing demand. WBL Peking University at present established in overseas markets, a number of brands (HypoCol / Lipascor), USA, Norway, Singapore, Japan, Korea, Hong Kong and Taiwan more than 10 countries and regions, exports reached 9.5 million U.S. dollars, for the Chinese contributed to the internationalization. In 2005, Xuezhikang approved in accordance with GCP standards of Taiwan's first completion of clinical studies of prescription medicine. In support of relevant government departments, the North-dimensional letter is currently being actively pursued Xuezhikang U.S. registration of new drugs, and explore a modern Chinese medicine market of their own road of internationalization. Recommended topics: Xinfu recurrence of the challenges of drug safety [Key words]: Monascus Comment Large In Small We are high quality suppliers, our products such as China irrigation solenoid valves , China pvc solenoid valves for oversee buyer. To know more, please visits cryogenic solenoid valves.
Related Articles -
China irrigation solenoid valves, China pvc solenoid valves,
|
